Does Asymmetric Expansion of Bioresorbable Vascular Scaffolds Cause Stent Failure?
作者信息
Hong Myeong-Ki, Kim Jung-Sun
机构信息
Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea; Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Korea; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea; Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Korea.
出版信息
JACC Cardiovasc Interv. 2016 Jun 27;9(12):1243-1245. doi: 10.1016/j.jcin.2016.04.026. Epub 2016 Jun 1.
PMID:27262864
Abstract
摘要
相似文献
1
Does Asymmetric Expansion of Bioresorbable Vascular Scaffolds Cause Stent Failure?
JACC Cardiovasc Interv. 2016 Jun 27;9(12):1243-1245. doi: 10.1016/j.jcin.2016.04.026. Epub 2016 Jun 1.
2
Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
Lancet. 2016 Feb 6;387(10018):537-544. doi: 10.1016/S0140-6736(15)00979-4. Epub 2015 Nov 17.
3
Is the Metallic Stent a Safe Treatment for Bioresorbable Scaffold Failure?: Insights From Optical Coherence Tomography.
JACC Cardiovasc Interv. 2016 May 9;9(9):976-7. doi: 10.1016/j.jcin.2016.02.031. Epub 2016 Apr 13.
4
First-in-human description of everolimus-eluting bioabsorbable vascular scaffold implantation for the treatment of drug-eluting stent failure: insights from optical coherence tomography.
Int J Cardiol. 2013 Oct;168(4):4490-1. doi: 10.1016/j.ijcard.2013.06.127. Epub 2013 Jul 24.
5
Very Late Bioresorbable Vascular Scaffold Thrombosis: Smoke or Fire?
JACC Cardiovasc Interv. 2017 Jan 9;10(1):38-41. doi: 10.1016/j.jcin.2016.11.038.
6
Optical coherence tomography evaluation of overlapping everolimus-eluting bioresorbable vascular scaffold implantation guided by enhanced stent visualization system.
Int J Cardiol. 2015 Mar 1;182:1-3. doi: 10.1016/j.ijcard.2014.12.103. Epub 2014 Dec 28.
7
Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
Circulation. 2010 Nov 30;122(22):2301-12. doi: 10.1161/CIRCULATIONAHA.110.970772. Epub 2010 Nov 15.
8
The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.
JACC Cardiovasc Interv. 2016 Jun 27;9(12):1231-1242. doi: 10.1016/j.jcin.2016.03.027. Epub 2016 Jun 1.
9
Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
JACC Cardiovasc Interv. 2014 Dec;7(12):1400-11. doi: 10.1016/j.jcin.2014.06.016.
10
Clinical Outcomes After Implantation of Overlapping Bioresorbable Scaffolds vs New Generation Everolimus Eluting Stents.
Rev Esp Cardiol (Engl Ed). 2016 Dec;69(12):1135-1143. doi: 10.1016/j.rec.2016.04.010. Epub 2016 Jun 2.
Zotero 插件